Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.80 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | BCL6 | P41182 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | TDP2 | O95551 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16208488 | 0.89 | KIF11 (1.00) | KIF11CRBN | |
| SCHEMBL16208518 | 0.88 | KIF11 (1.00) | KIF11PTK2BGAA | |
| SCHEMBL28837814 | 0.84 | KIF11 (0.63) | KIF11PTK2BGAABCL6CRBN | |
| SCHEMBL578303 | 0.83 | TDP2 (0.66) | KIF11GAATDP2 | |
| SCHEMBL31492431 | 0.83 | TDP2 (0.66) | KIF11GAATDP2 | |
| SCHEMBL1903306 | 0.82 | KIF11 (0.80) | KIF11GAATDP2 | |
| SCHEMBL28119242 | 0.81 | AHR (0.68) | KIF11PTK2BGAABCL6CRBN | |
| SCHEMBL16208485 | 0.81 | KIF11 (0.85) | KIF11CRBN | |
| SCHEMBL4405155 | 0.79 | PKM (0.65) | KIF11GAA | |
| SCHEMBL16208463 | 0.79 | KIF11 (1.00) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506763-B2 | Useful in prevention and treatment of protein kinase related disorders such as cancer | SUGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020026053-A1 | Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of protein kinase activity | TANG PENG CHO (US) | 2002-02-28 | — | — | US | disclosed |
| US-20010007033-A1 | Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity | SUGEN, INC. | 2001-07-05 | — | — | US | disclosed |
| US-6133305-A | PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026053-A1 | Novel 3-(substituted) -2- indolinones compounds and use thereof as inhibitors of protein kinase activity | MAP3K20, SBK3, MAP4K2 | KIF11 4257/4885PTK2B 94/4885GAA 2413/4885 |
| US-20010007033-A1 | Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity | SBK3, MAP4K2, MAP3K20 | KIF11 4316/4885PTK2B 99/4885GAA 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.